TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03917381

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acasunlimab
Description: Acasunlimab will be administered intravenously once every 21 days (in selected expansion cohorts acasunlimab will be administered intravenously once every 21 days for the first 2 cycles, and every 42 days in subsequent cycles).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acasunlimab
Description: Acasunlimab will be administered intravenously once every 21 days (in selected expansion cohorts acasunlimab will be administered intravenously once every 21 days for the first 2 cycles, and every 42 days in subsequent cycles).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acasunlimab in combination with docetaxel (in a single expansion cohort)
Description: Acasunlimab and docetaxel will be administered intravenously once every 21 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)
Description: Acasunlimab and pembrolizumab will be administered intravenously once every 21 days or every 42 days, respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Description: Acasunlimab and pembrolizumab and standard chemotherapy will be administered intravenously once every 21 days for 4 cycles, followed by treatment with acasunlimab and pembrolizumab once every 21 days.
Study: NCT02888743

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT01779050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Study: NCT01613417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gadoteridol
Description: ProHance 0.1 mmol/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gadoteridol
Description: ProHance 0.1 mmol/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gadobutrol
Description: Gadovist/Gadavist 0.1 mmol/kg
Study: NCT02888743

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT04143724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-536
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-536
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-536
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-536
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-536
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-536
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-536
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-536
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-536
Description: Specified dose on specified days
Study: NCT02715076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient Temperature 21°C
Description: Ambient Temperature 21°C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient Temperature 21°C
Description: Ambient Temperature 21°C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient Temperature 23°C
Description: Ambient Temperature 23°C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient Temperature 23°C
Description: Ambient Temperature 23°C

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forced-air cover (Bair hugger 63500, 3M)
Description: Patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
Study: NCT03587805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.
Study: NCT02715076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forced-air cover (Bair hugger 63500, 3M)
Description: Patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forced-air cover (Bair hugger 63500, 3M)
Description: Patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
Study: NCT04650568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Derived Mesenchymal Stem Cells
Description: Autologous Bone Marrow Derived Mesenchymal Stem Cells injected into the ACL allograft prior to graft implantation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham incision
Description: Small incision over the site where bone marrow aspirate would have been obtained
Study: NCT02682927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX008 (Fenfluramine Hydrochloride)
Description: ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5. The product is sugar free and is intended to be compatible with a ketogenic diet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX008 (Fenfluramine Hydrochloride)
Description: ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5. The product is sugar free and is intended to be compatible with a ketogenic diet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo solution for ZX008. The product is sugar free and is intended to be compatible with a ketogenic diet.
Study: NCT01613417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gadobutrol
Description: Gadovist/Gadavist 0.1 mmol/kg
Study: NCT02202317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT Scan
Description: Subjects will receive a PET/CT Scan in addition to SPECT imaging, from the level of the lower chest to the lower pelvis, typical of an abdominal CT, usually within 1-3 hours after Yttrium-90 treatment.
Study: NCT02715076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive insulation
Description: Patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive insulation
Description: Patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive insulation
Description: Patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
Study: NCT02036463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study: NCT03950076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Edoxaban 60mg (or 30mg as determined by clinical criteria)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-anticoagulant medical therapy
Description: Non-anticoagulant medical therapy as determined by the local investigator includes i) No antithrombotic therapy ii) Antiplatelet monotherapy, including de novo indication for antiplatelet monotherapy during course of the study
Study: NCT02989948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physician-modified aortic endograft
Description: Use of physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physician-modified aortic endograft
Description: Use of physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
Study: NCT04012606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TORIPALIMAB INJECTION(JS001 ) Carboplatin Cisplatin Etoposide Placebo
Description: TORIPALIMAB INJECTION(JS001 ) or Placebo combined with chemotherapy, 240mg/6ml/vial, Q3W,up to 2 years of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORIPALIMAB INJECTION(JS001 ) Carboplatin Cisplatin Etoposide Placebo
Description: TORIPALIMAB INJECTION(JS001 ) or Placebo combined with chemotherapy, 240mg/6ml/vial, Q3W,up to 2 years of treatment.
Study: NCT04016662

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tandem t:slim X2 with HCL or PLGS
Description: The system components include the t:slim X2 with Control-IQ Technology and the Dexcom CGM G6. The modular control algorithm has a safety supervision module that limits insulin delivery to prevent hypoglycemia at all times. The algorithm gradually decreases hyperglycemia from bedtime to reach a target of 120 mg/dL by waking time. During awake hours, the control algorithm attempts to maintain glucose within a target range (112.5 to 160 mg/dL) with meal time insulin boluses delivered based on usual bolus procedures undertaken by patients on an insulin pump (Hybrid closed loop).~The system components include the t:slim X2 with with Basal-IQ Technology and the Dexcom CGM G6. The PLGS System is able to stop and resume basal insulin delivery automatically in response to predicted or low sensor glucose values, thereby reducing the incidence and duration of hypoglycemic episodes. The pump includes the hypoglycemia minimization strategy that will issue insulin delivery commands.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tandem t:slim X2 with HCL or PLGS
Description: The system components include the t:slim X2 with Control-IQ Technology and the Dexcom CGM G6. The modular control algorithm has a safety supervision module that limits insulin delivery to prevent hypoglycemia at all times. The algorithm gradually decreases hyperglycemia from bedtime to reach a target of 120 mg/dL by waking time. During awake hours, the control algorithm attempts to maintain glucose within a target range (112.5 to 160 mg/dL) with meal time insulin boluses delivered based on usual bolus procedures undertaken by patients on an insulin pump (Hybrid closed loop).~The system components include the t:slim X2 with with Basal-IQ Technology and the Dexcom CGM G6. The PLGS System is able to stop and resume basal insulin delivery automatically in response to predicted or low sensor glucose values, thereby reducing the incidence and duration of hypoglycemic episodes. The pump includes the hypoglycemia minimization strategy that will issue insulin delivery commands.
Study: NCT04242095

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of tissue, blood, and stool samples

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical records
Study: NCT02193386

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention, no follow-up, only registration
Description: Usual Care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention period
Description: Predefined intervention program
Study: NCT05611229

Intervention type: DRUG
Intervention: Nivolumab
Description: Nivolumab

Intervention type: DRUG
Intervention: Nivolumab
Description: Nivolumab

Intervention type: DRUG
Intervention: Pembrolizumab
Description: Pembrolizumab

Intervention type: DRUG
Intervention: Pembrolizumab
Description: Pembrolizumab

Intervention type: COMBINATION_PRODUCT
Intervention: Dabrafenib+Trametinib
Description: Dabrafenib+Trametinib

Intervention type: COMBINATION_PRODUCT
Intervention: Dabrafenib+Trametinib
Description: Dabrafenib+Trametinib

Intervention type: COMBINATION_PRODUCT
Intervention: Ipilimumab+Nivolumab
Description: Ipilimumab+Nivolumab

Intervention type: COMBINATION_PRODUCT
Intervention: Vemurafenib+Cobimetinib
Description: Vemurafenib+Cobimetinib

Intervention type: COMBINATION_PRODUCT
Intervention: Encorafenib+Binimetinib
Description: Encorafenib+Binimetinib
Study: NCT02729610

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: double-lumen endotracheal tube (DLT group)
Description: In this arm, after anesthesia induction, a double lumen endotracheal tube will be intubated for one-lung ventilation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endobronchial blocker (BB group)
Description: In this arm, after anesthesia induction, an endobronchial blocker will be intubated for one-lung ventilation
Study: NCT00524953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUMATRON - EN 600 NT
Description: frequency - once a week, starting 4 days after transplantation for four weeks (total of 4 treatments) each treatment will last \~20 minutes. In addition - standard GVHD preventive protocol will be given to patients (including cyclosporine and steroids - if necessary)
Study: NCT01671501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email Feedback

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Study: NCT02036463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03412266

Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France).
Study: NCT00385606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Study: NCT02036463

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00829946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Participants in the intervention group were enrolled in two training sessions per week for 12 weeks. The core portion of the training session consisted of 11 strength exercises engaging the major muscle groups, i.e. bench press, shoulder press, leg extension, leg press, leg curl, abdominal crunch, low back extension, arm curl, elbow extension, seated row and lateral pull-down. For each exercise, the participants performed one set of 8-15 repetitions (total of \~ 20s duration) with resting periods of 1-2 min between exercises. The load was gradually increased as the strength of each child improved, i.e. from 20-30% of 6 repetition maximum (6RM) at the start of the program to 50-60% of 6RM at the end. Participants also performed isometric contractions of large muscle groups (6 sets of 3 repetitions each, 20-30s duration per repetition) with their own body weight (for lower body exercises) or barbells (1-3kg) for upper body.
Study: NCT03615976

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high tibial osteotomy with or without arthroscopic circumpatellar denervation with or without arthroscopic circumpatellar denervation
Description: Arthroscopy will be done in all cases before osteotomy to assess lat. Comp and grade of patellofemoral O.A Arthroscopic patellar denervation with vaper or diathermy will be done plus open wedge high tibial osteotomy in one group and other group OWHTO only will be done comparing the rustles of two groups to assess the efficacy of this procedure~followed by an average follow up to 12 months. And follow up( 6th weeks ,3rd month ,6th month , 12th month)~By clinical examinationan and x-ray and knee scores~1. Scoring of patellofemoral disorders( Kujala) score~2. Knee Injury and Osteoarthritis Outcome Score (KOOS)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high tibial osteotomy with or without arthroscopic circumpatellar denervation with or without arthroscopic circumpatellar denervation
Description: Arthroscopy will be done in all cases before osteotomy to assess lat. Comp and grade of patellofemoral O.A Arthroscopic patellar denervation with vaper or diathermy will be done plus open wedge high tibial osteotomy in one group and other group OWHTO only will be done comparing the rustles of two groups to assess the efficacy of this procedure~followed by an average follow up to 12 months. And follow up( 6th weeks ,3rd month ,6th month , 12th month)~By clinical examinationan and x-ray and knee scores~1. Scoring of patellofemoral disorders( Kujala) score~2. Knee Injury and Osteoarthritis Outcome Score (KOOS)
Study: NCT00299455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin-clavulanate
Description: Amoxicillin clavulanate 40 mg/kg/day divided into two daily doses for 7 days. Capsules will be produced by pulverizing amoxicillin clavulanate tablets (Augmentin 875 mg; manufacturer Glaxo SmithKline Beecham; ATC Code: J01CR02) and mixing that with lactose monohydrate. Each capsule will contain Augmentin tablet powder 68 mg and lactose monohydrate 572 mg. This means amoxicillin 40 mg and clavulanate 5,7 mg respecting the dose per 2 kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice a day for 7 days. Placebo capsules contain lactose monohydrate 640 mg.
Study: NCT02855216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual technique of sub-occipital inhibition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-treatment by way of Occipivot®
Study: NCT04505774

Intervention type: DRUG
Group type: OTHER
Intervention: theraputic heparin
Description: increased dose of heparin above standard of care.

Intervention type: DRUG
Group type: OTHER
Intervention: theraputic heparin
Description: increased dose of heparin above standard of care.
Study: NCT00385606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prolonged continuous infusion gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prolonged continuous infusion gemcitabine
Study: NCT04505774

Intervention type: DRUG
Group type: OTHER
Intervention: prophylactic heparin
Description: standard of care dose of heparin

Intervention type: DRUG
Group type: OTHER
Intervention: prophylactic heparin
Description: standard of care dose of heparin

Intervention type: DRUG
Group type: OTHER
Intervention: P2Y12
Description: added P2Y12 inhibitor

Intervention type: DRUG
Group type: OTHER
Intervention: P2Y12
Description: added P2Y12 inhibitor

Intervention type: DRUG
Group type: OTHER
Intervention: Crizanlizumab Injection
Description: crizanlizumab injection
Study: NCT00385606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Study: NCT04505774

Intervention type: DRUG
Group type: OTHER
Intervention: Crizanlizumab Injection
Description: crizanlizumab injection
Study: NCT00385606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rofecoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rofecoxib
Study: NCT01333449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20mg/m\^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.
Study: NCT03378791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron bisglycinate Oral Tablet
Study: NCT03782467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATOR-1015
Description: Bispecific human monoclonal antibody targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and OX40 (also known as CD134)
Study: NCT04062513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactive stimulation intervention with familiarization
Description: The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick. For the familiarization stage, infants were familiarized with the odor of their mothers' milk for 9 hours before heel prick.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactive stimulation intervention
Description: The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Preterm infants will receive sucrose during heel prick.
Study: NCT04505774

Intervention type: DRUG
Group type: OTHER
Intervention: SGLT2 inhibitor
Description: sglt2 inhibitor